Cardiology

A recent study found that telerehabilitation was comparable to traditional in-clinic rehabilitation for stroke patients.

Recent analysis of 3 trials found that CERT2 showed comparable and synergistic predictive performance when compared with previously published CVD risk models.

Analysis of the SURTAVI clinical trial revealed that TAVR and SAVR are both safe for patients with a CABG history.

Survey of 3000 found that more than half of all respondents wish they knew more about heart failure but just 1 in 5 were likely to speak with their doctor out of fear of diagnosis or cost.

A recent study from investigators at Michigan State University found that vitamin D supplementation was not associated with reduced risk of major cardiovascular events.

Christopher Sorli, MD, vice president of medical affairs at Sanofi, discusses the results of a recent trial examining insulin glargine plus lixisenatide.

After Janssen's submission of an sNDA in March, results of the CREDENCE subgroup analyses were among the most anticipated presentations at ADA 2019.

A study presented at ADA 2019 examined the efficacy of sitagliptin compared with dapagliflozin in t2d patients 65 years old and older.

Oral anticoagulant choice in the obese; how to reduce inflammation in atherosclerosis; and optimal DAPT duration post-PCI. Top-line reviews of 3 new studies highlight potential for practice change.

Osama Hamdy, MD, PhD, discusses the impact of a 10-year study observing the impact of lifestyle interventions among diabetes patients in real-world clinical practice.

A new study shows patients with T1D and comorbid cardiovascular disease face a signficantly greater cost of care.

An analysis of 7 trials examining cardiovascular outcomes of study drugs found that concomitant insulin use increased a patient’s risk of severe cardiovascular outcomes.

Investigators from Allegheny Health Network examined the impact of a multidisciplinary team approach on glycemic control in patients with diabetes in a primary care setting.

Up to 77% of the increased CVD risk associated with preeclampsia and gestational hypertension is associated with conventional risk factors like BMI and blood pressure.

A high consumption of ultra-processed foods (i.e. almost any consumable food item, except fresh fruits and vegetables) is associated with an increased risk of cardiovascular disease and mortality, show two studies in BMJ.

An analysis of results from the EXSCEL trial has suggested that exenatide with SGLT2 inhibitors may reduce major cardiovascular events and improve renal health.

A new retrospective cohort analysis found that patients with type 2 diabetes generally have about 12 months following BI initiation to achieve A1c < 7.0%.

Type 2 diabetes patient outcomes including heart failure, stroke, and myocardial infarction were weighed between the 2 popular drug classes.

A study of the massive 2005 trial data found that fenofibrate-targeted biomarkers are closely associated to cardiovascular risks in patients with T2D.

A study into the impact of the timing of glucose blood readings has found that being 15 to 25 minutes late can almost double a patient's risk of hypoglycemia.

A decision for icosapent ethyl's sNDA is not expected to come from the FDA until September, but excitement surrounding the drug is at all-time high.

Early initiation of GLP-1RA and SGLT2 in patients with T2D resulted in higher odds for long term HbA1C control and for lower CV risk factors.

The longest clinical assessment of a GLP-1 receptor agonist for cardiovascular outcomes showed a 12% decrease in MACE versus placebo.

An age-stratified analysis of Swedish national registry data found that myocardial infarction and heart failure rates may even be more prevalent in patients with T1D.

Sue Kirkman, MD, professor of medicine at UNC Chapel Hill, discusses the results of a study she led that attempted to create a method of identifying what type of diabetes through EHR data.

John Buse, MD, professor of medicine at UNC Chapel Hill, discusses the results and implications of the PIONEER 7 trial.

It's been 5 years since the FDA approved empagliflozin, and 4 since the major outcomes findings. What is its role in diabetes care today?

The three-year trial reported that initial weight loss plus 1 of any 4 diet and exercise programs is associated with major benefits for at-risk patients.

A review of REDUCE-IT data prior to an FDA supplemental new drug application decision shows the unprecedented benefit of the fish oil therapy.

Todd Hobbs, MD, chief medical officer of Novo Nordisk North America, discusses the results of PIONEER 4 at ADA 2019 in San Francisco, CA.